{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/","result":{"pageContext":{"chapter":{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol","depth":2,"htmlHeader":"<!-- begin field b9e1fc78-5b39-4a8f-883a-541c5289cbbb --><h2>Scenario: Paracetamol</h2><!-- end field b9e1fc78-5b39-4a8f-883a-541c5289cbbb -->","summary":"Covers prescribing information on paracetamol, including information on adverse effects, interactions, safety in pregnancy and breastfeeding, and general advice.","htmlStringContent":"<!-- begin item e34599f2-e487-469d-8211-322e27e238a3 --><!-- begin field d2cdb797-7838-4651-b1c9-acd900ad05d1 --><p>From age 3 months onwards.</p><!-- end field d2cdb797-7838-4651-b1c9-acd900ad05d1 --><!-- end item e34599f2-e487-469d-8211-322e27e238a3 -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","lastRevised":"Last revised in August 2020","chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","fullItemName":"Management","slug":"management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c0306372-f90b-5a53-a2b3-33533b194418","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 90285d91-9980-4aed-8b3f-8e6e399d4a18 --><h3>What are the contraindications and cautions for paracetamol?</h3><!-- end field 90285d91-9980-4aed-8b3f-8e6e399d4a18 -->","summary":null,"htmlStringContent":"<!-- begin item 6814340d-5758-46d1-8c4f-d4324073fdb6 --><!-- begin field 36a38a8a-f928-4af2-bd6f-48fea3cd94c4 --><ul><li><strong>There are no contraindications to the use of paracetamol.</strong></li><li><strong>Prescribe paracetamol with caution (and consider a <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#recommended-doses\">dose reduction</a>):</strong><ul><li>If there are risk factors for hepatotoxicity and inadvertent paracetamol overdose, including:<ul><li>Alcohol dependency.</li><li>Malnutrition.</li><li>Chronic dehydration.</li><li>Body weight less than 50 kg.</li><li>Severe liver disease — pharmacokinetics of paracetamol is altered in severe liver disease, and the hazards of overdose are greater in people with non-cirrhotic alcoholic liver disease.</li><li>Increasing age and/or frailty — a reduction of the clearance of paracetamol has been associated with increased age and frailty. In addition, elderly people have comorbidities and polypharmacy, which can further increase risk of inadvertent paracetamol toxicity and overdose.</li><li>The use of liver enzyme-inducing drugs (such as rifampicin, carbamazepine, and phenytoin) — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#drug-interactions\">Drug interaction</a> for more information.</li></ul></li></ul></li><li><strong>Avoid effervescent preparations of paracetamol where possible, </strong>particularly in people with hypertension, heart failure, and renal failure — if oral paracetamol is required in a person with swallowing difficulty, use paracetamol suspension in place of effervescent preparations (which contains up to 6 g salt in a 4 g per 24 hours dose).</li></ul><!-- end field 36a38a8a-f928-4af2-bd6f-48fea3cd94c4 --><!-- end item 6814340d-5758-46d1-8c4f-d4324073fdb6 -->","subChapters":[{"id":"b5c0abff-e8a3-532c-94f4-6f8d72c91826","slug":"basis-for-recommendation-613","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a2807cd9-7d70-421a-9ff4-2e1ded20a450 --><h4>Basis for recommendation</h4><!-- end field a2807cd9-7d70-421a-9ff4-2e1ded20a450 -->","summary":null,"htmlStringContent":"<!-- begin item 613416b0-564f-4dee-a7b2-e1f183fef6eb --><!-- begin field 12d4dfbb-9b2a-4b6e-9478-6865b73cbfee --><h5>Contraindications</h5><ul><li>The Summary of Product Characteristics (SPC) for paracetamol [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">BNF, 2020</a>] do not list any contraindications for paracetamol.</li></ul><h5>Cautions</h5><ul><li>The SPC and the BNF advise caution in chronic alcohol consumption, chronic dehydration, chronic malnutrition, hepatocellular insufficiency, and long-term use (especially in those who are malnourished), but no dose reduction is advised for these groups of people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</li><li>Caution is also advised in the NHS Borders Medication Safety Action Committee <em>Medication Safety Bulletin</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Borders, 2012</a>], the Leeds Teaching Hospital NHS Trust guideline <em>Reducing oral paracetamol doses in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Leeds Teaching Hospitals NHS Foundation Trust, 2020</a>], and the NHS Wales guideline <em>Prescribing paracetamol in patients aged 16 and over</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Wales, 2018</a>].</li><li>There have been documented reports of liver damage (one fatal) in people weighing less than 50 kg when given the standard dose (1 g four times daily) of paracetamol.<ul><li>The Medicines and Healthcare Products and Regulatory Agency (MHRA) has reviewed the literature since these reports and concluded that the people in these case reports had pre-existing risk factors, such as chronic malnutrition or high alcohol consumption, which are known indications for considering a dose reduction of oral paracetamol.</li><li>Although the MHRA concluded that a person’s weight being less than 50 kg is not in itself an indication to reduce the dose of oral paracetamol, consideration should be given to lowering the dose in people with other conditions likely to pre-dispose them to liver damage from paracetamol. Low body weight is often an indication that the person may have other chronic conditions that increases their risk of toxicity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Leeds Teaching Hospitals NHS Foundation Trust, 2020</a>].</li></ul></li></ul><!-- end field 12d4dfbb-9b2a-4b6e-9478-6865b73cbfee --><!-- end item 613416b0-564f-4dee-a7b2-e1f183fef6eb -->","subChapters":[]}]},{"id":"f46b8ea5-4c53-56d7-bcf2-8cb4d3c43583","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field 07139c85-a4a3-4cae-a73f-1c8133ef0741 --><h3>What dose of paracetamol should I prescribe?</h3><!-- end field 07139c85-a4a3-4cae-a73f-1c8133ef0741 -->","summary":null,"htmlStringContent":"<!-- begin item c4e1ef87-500f-452b-95ee-d46b60d0361f --><!-- begin field 4db732ae-61db-47c9-bf83-e341e32bf52b --><ul><li><strong>The recommended doses of paracetamol for people aged 18 years and older are:</strong><ul><li>By mouth — 500 mg to 1 g every 4 to 6 hours as required (maximum 4 g in 24 hours).</li><li>By rectum — 500 mg to 1 g every 4 to 6 hours as required (maximum 4 g in 24 hours).</li></ul></li><li><strong>The recommended doses of paracetamol for children aged up to 17 years are shown in Table 1 below. </strong>These doses may be repeated every 4 to 6 hours if necessary (maximum of four doses in 24 hours).</li></ul><p><strong>Table 1.</strong> Recommended doses of paracetamol for children aged up to 17 years.</p><table data-table-id=\"47278b8f-38f3-41ae-a444-acce00f78b5a\"><thead><tr><th scope=\"col\"><strong>Age</strong></th><th scope=\"col\"><strong>Dose</strong></th></tr></thead><tbody><tr><td colspan=\"2\"><strong>Oral dose</strong></td></tr><tr><td>3–5 months</td><td>60 mg</td></tr><tr><td>6–23 months</td><td>120 mg</td></tr><tr><td>2–3 years</td><td>180 mg</td></tr><tr><td>4–5 years</td><td>240 mg</td></tr><tr><td>6–7 years</td><td>240–250 mg</td></tr><tr><td>8–9 years</td><td>360–375 mg</td></tr><tr><td>10–11 years</td><td>480–500 mg</td></tr><tr><td>12–15 years</td><td>480–750 mg</td></tr><tr><td>16–17 years</td><td>500 mg–1000 mg (1 g)</td></tr><tr><td colspan=\"2\"><strong>Rectal dose</strong></td></tr><tr><td>3–11 months</td><td>60–125 mg</td></tr><tr><td>1–4 years</td><td>125–250 mg</td></tr><tr><td>5–11 years</td><td>250–500 mg</td></tr><tr><td>12–17 years</td><td>500 mg</td></tr></tbody></table><ul><li><strong>Use clinical judgement to adjust the dose of oral paracetamol in people with risk factors for hepatotoxicity and paracetamol overdose,</strong> for example, people with liver disease and people with body weight less than 50 kg. If <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#contraindications-cautions\">risk factors</a> are present:<ul><li>Consider reducing the total daily dose of paracetamol as follows:<ul><li>Body weight 30–39 kg — prescribe 15 mg per kg per dose. The final dose should be determined on an individual basis (maximum of 60 mg per kg in 24 hours; use oral suspension if necessary).</li><li>Body weight 40–49 kg — prescribe 500 mg to 1 g every 6 hours as required (maximum 3 g in 24 hours, for example, prescribe 1 g three times daily).</li><li>Body weight more than 50 kg — prescribe 500 mg to 1 g every 4 to 6 hours as required (maximum 3 g in 24 hours).</li></ul></li><li>Monitor liver function tests if increased. </li><li>Advise the person that they have been prescribed a lower dose and explain the reason why.<ul><li>Advise caution when using over-the-counter paracetamol-containing products; the recommended maximum total daily dosage must not be exceeded.</li><li>Explain that the lower dose of paracetamol may not be stated in the manufacturer's patient information leaflet.</li></ul></li></ul></li></ul><!-- end field 4db732ae-61db-47c9-bf83-e341e32bf52b --><!-- end item c4e1ef87-500f-452b-95ee-d46b60d0361f -->","subChapters":[{"id":"b802d96a-2c66-5be2-989c-68b3344bdca6","slug":"basis-for-recommendation-00c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e9d8c7cb-70f9-4c8d-94db-d6eefa1b96c0 --><h4>Basis for recommendation</h4><!-- end field e9d8c7cb-70f9-4c8d-94db-d6eefa1b96c0 -->","summary":null,"htmlStringContent":"<!-- begin item 00c3e615-60b1-460e-ae2a-2161f911deb2 --><!-- begin field 16490f3d-4fd8-45f7-9e76-b62a825821ec --><h5>Recommended doses of paracetamol for most people</h5><ul><li>These recommendations are based on the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</li></ul><h5>Recommended doses of paracetamol for people with risk factors for hepatotoxicity and paracetamol overdose</h5><ul><li><p>These recommendations are based on expert opinion in the NHS Borders Medication Safety Action Committee <em>Medication Safety Bulletin</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Borders, 2012</a>], the Leeds Teaching Hospital NHS Trust guideline <em>Reducing oral paracetamol doses in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Leeds Teaching Hospitals NHS Foundation Trust, 2020</a>], and the NHS Wales guideline <em>Prescribing paracetamol in patients aged 16 and over</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NHS Wales, 2018</a>].</p></li></ul><!-- end field 16490f3d-4fd8-45f7-9e76-b62a825821ec --><!-- end item 00c3e615-60b1-460e-ae2a-2161f911deb2 -->","subChapters":[]}]},{"id":"75b7318f-8d82-540f-b3f8-5a9970cdc93b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b5fcc5b3-9f47-4cfb-9d49-468c1db3226d --><h3>What are the adverse effects of paracetamol?</h3><!-- end field b5fcc5b3-9f47-4cfb-9d49-468c1db3226d -->","summary":null,"htmlStringContent":"<!-- begin item 5a52000c-a13e-4bf7-8889-07de8cc0da6d --><!-- begin field b531e1d6-2c3c-47c8-9a3a-5831a87d992d --><ul><li><strong>Adverse effects are rare with paracetamol.</strong></li><li><strong>Blood dyscrasias (including thrombocytopenia and agranulocytosis) </strong>have been rarely reported in people taking oral paracetamol, but it is not clear that these were directly caused by the paracetamol.</li><li><strong>Other possible adverse effects of paracetamol include:</strong><ul><li>Common or very common:<ul><li>Rectal — anorectal erythema.</li></ul></li><li>Rare or very rare:<ul><li>Rectal— angioedema, liver injury, skin reactions.</li></ul></li><li>Frequency unknown: <ul><li>Oral — abnormal hepatic function, agranulocytosis, bronchospasm, rash, and severe cutaneous adverse reactions (SCARs).</li><li>Rectal — agranulocytosis, blood disorder, and SCARs.</li></ul></li></ul></li><li><strong>Liver damage and renal damage (less frequent) can occur in people who have taken 10 g or more of paracetamol.</strong> Ingestion of 5 g or more may lead to liver damage if the person has risk factors for liver damage, including alcohol dependence, pre-existing liver disease, malnutrition, and the use of liver enzyme-inducing drugs (such as rifampicin, carbamazepine, and phenytoin).<ul><li>Early symptoms of paracetamol overdose (seen in the first 24 hours) are pallor, nausea, vomiting, and abdominal pain.</li><li>Liver damage may become apparent 12–48 hours after ingestion, and symptoms include right subcostal pain and tenderness. In severe poisoning, the person may develop encephalopathy, haemorrhage, hypoglycaemia, and cerebral oedema.</li><li>Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria, and proteinuria, may develop even in the absence of severe liver damage. </li><li>People who have taken an overdose of paracetamol may require immediate hospital admission depending on the quantity of paracetamol taken and the presence of risk factors for liver damage. See the <a data-hyperlink-id=\"5f775fed-6569-42d1-82b5-a93100961dec\" href=\"https://www.toxbase.org/\">TOXBASE website</a> or telephone the National Poisons Information Services (NPIS) on 0344 892 0111 for advice on when admission is required.</li></ul></li></ul><!-- end field b531e1d6-2c3c-47c8-9a3a-5831a87d992d --><!-- end item 5a52000c-a13e-4bf7-8889-07de8cc0da6d -->","subChapters":[{"id":"e432e38e-ecb1-5115-8c57-bd29c42e4f09","slug":"basis-for-recommendation-f0c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 45f4258d-a82c-48cd-8de6-ee215a8d0feb --><h4>Basis for recommendation</h4><!-- end field 45f4258d-a82c-48cd-8de6-ee215a8d0feb -->","summary":null,"htmlStringContent":"<!-- begin item f0cabf64-38c4-4972-927c-759f028b5004 --><!-- begin field 30a13d36-657f-4490-93bd-1ed59be4c5c6 --><p>This information is based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 30a13d36-657f-4490-93bd-1ed59be4c5c6 --><!-- end item f0cabf64-38c4-4972-927c-759f028b5004 -->","subChapters":[]}]},{"id":"fba08a25-d948-5e7e-a733-b86e93d9ed6d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b8ea4a3f-eeda-4468-afd8-b391f676727e --><h3>What are the key drug interactions with paracetamol and how should I manage them?</h3><!-- end field b8ea4a3f-eeda-4468-afd8-b391f676727e -->","summary":null,"htmlStringContent":"<!-- begin item a62d3619-f587-4b0b-9efa-4e1bc64c23da --><!-- begin field 341e6ecb-534e-493e-b146-4e86239c5465 --><ul><li><strong>Drug interactions with paracetamol include:</strong><ul><li>Alcohol — excessive alcohol consumption causes severe liver damage when given with paracetamol. Also, paracetamol and alcohol can increase the risk of hepatotoxicity.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li>Anticoagulants — the effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol, with increased risk of bleeding. Occasional doses have no significant effect.<ul><li>Monitor international normalized ratio (INR).</li></ul></li><li>Colestyramine — may reduce absorption if given within 1 hour of paracetamol.<ul><li>Separate administration by 1 to 2 hours.</li></ul></li><li>Domperidone and metoclopramide — may increase speed of absorption of paracetamol.</li><li>Liver enzyme-inducing drugs — the use of liver enzyme-inducing drugs (such as rifampicin, carbamazepine, and phenytoin) can increase the risk of hepatotoxicity.<ul><li>Consider a paracetamol <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#recommended-doses\">dose reduction</a>.</li></ul></li></ul></li><li><strong>See the <a data-hyperlink-id=\"91bc0f7b-d72b-417f-93d9-a98c00d870a8\" href=\"http://www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"27c10c25-b695-4ce5-b76d-a98c00d87121\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF) for a list of all possible drug interactions with paracetamol.</strong></li></ul><!-- end field 341e6ecb-534e-493e-b146-4e86239c5465 --><!-- end item a62d3619-f587-4b0b-9efa-4e1bc64c23da -->","subChapters":[{"id":"6d60ae8f-47e2-52fa-a539-1dc644e2e761","slug":"basis-for-recommendation-00a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field eb2c0f22-5e91-4a35-8bec-7ac611c516fe --><h4>Basis for recommendation</h4><!-- end field eb2c0f22-5e91-4a35-8bec-7ac611c516fe -->","summary":null,"htmlStringContent":"<!-- begin item 00abbe5f-9951-4626-aedd-7bfed3a685d8 --><!-- begin field b261ef84-c8be-4b3e-a82a-785b8857ca07 --><p>This information is based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>]<em> </em>and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field b261ef84-c8be-4b3e-a82a-785b8857ca07 --><!-- end item 00abbe5f-9951-4626-aedd-7bfed3a685d8 -->","subChapters":[]}]},{"id":"0497a0cd-4524-5c3d-aea7-37c869fbb15e","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 1950c5d1-c180-4e91-9d6b-c9a5c7c01313 --><h3>Can I prescribe paracetamol to a woman who is pregnant or breastfeeding?</h3><!-- end field 1950c5d1-c180-4e91-9d6b-c9a5c7c01313 -->","summary":null,"htmlStringContent":"<!-- begin item eefe73a2-fef9-414f-98f7-f3c2d3e956fd --><!-- begin field a4d38805-29c0-49bd-b485-dbdb6bc4b01c --><ul><li><strong>Pregnancy</strong><ul><li>Paracetamol is the analgesic of choice for women who are trying to conceive or who are pregnant.</li><li>It can be used at the <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#recommended-doses\">standard dose</a> at any stage of pregnancy.</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Paracetamol is the analgesic of choice for women who are breastfeeding.</li><li>Very small amounts of paracetamol pass into the breast milk, and these amounts are far below the doses that would normally be given to infants directly.</li><li>Seek specialist advice if:<ul><li>The infant is pre-term or low birth weight.</li><li>The absorption, distribution, metabolism, or excretion of paracetamol may be affected by an underlying medical condition in the infant.</li><li>The mother is taking multiple medicines.</li></ul></li></ul></li></ul><!-- end field a4d38805-29c0-49bd-b485-dbdb6bc4b01c --><!-- end item eefe73a2-fef9-414f-98f7-f3c2d3e956fd -->","subChapters":[{"id":"4fcfaf08-6702-56a1-8d38-b1376d6648c6","slug":"basis-for-recommendation-2ba","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 680238e4-095d-4d55-b16a-35b25afac794 --><h4>Basis for recommendation</h4><!-- end field 680238e4-095d-4d55-b16a-35b25afac794 -->","summary":null,"htmlStringContent":"<!-- begin item 2ba45ccc-8da7-4b46-89b5-687fe96f6a64 --><!-- begin field d4e51f6b-e988-4e5a-8bae-d5e2af8fa6c6 --><h5>Pregnancy</h5><ul><li>Paracetamol has been used by pregnant women for many years without any obvious harmful effects on the developing baby. For this reason, it is usually recommended as the analgesic of choice for pregnant women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2017a</a>].</li><li>The UK Teratology Information Service (UKTIS) states that an association with an increased risk of any adverse fetal outcome following therapeutic paracetamol use in pregnancy remains to be proven [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2017b</a>].</li><li>The manufacturer states that if clinically needed, paracetamol can be used during pregnancy. However, it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>].</li></ul><h5>Breastfeeding</h5><ul><li>There is very little published evidence on the use of paracetamol during breastfeeding.</li><li>Evidence from five small studies identified by the UK Medicines Information (UKMi) showed that very small amounts of paracetamol pass into the breast milk and these amounts are far below the doses that would normally be given to infants directly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKMI, 2020</a>].</li><li>With the exception of one possible hypersensitivity reaction in a single case report, no adverse effects have been reported in breastfeeding infants whose mothers have taken paracetamol in over 50 years of use in the UK.<ul><li>In the case report, a mother was given 1 g of paracetamol at bedtime for 2 days after which a maculopapular rash appeared on the infant’s chest and face. The rash disappeared 24 hours after the paracetamol was discontinued but reappeared when the mother was given another 1 g dose of paracetamol 2 weeks later [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKMI, 2020</a>].</li></ul></li><li>The manufacturer states that paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breastfeeding with paracetamol [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020d</a>].</li></ul><!-- end field d4e51f6b-e988-4e5a-8bae-d5e2af8fa6c6 --><!-- end item 2ba45ccc-8da7-4b46-89b5-687fe96f6a64 -->","subChapters":[]}]},{"id":"99f1f6b4-5a80-50d2-ab87-d3162ee13c3a","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 8cc203c5-bc3a-4c75-b1b6-74e930138ae2 --><h3>What information and advice should I give to a person receiving paracetamol?</h3><!-- end field 8cc203c5-bc3a-4c75-b1b6-74e930138ae2 -->","summary":null,"htmlStringContent":"<!-- begin item f67372b5-7585-44e5-a979-c2b03984f569 --><!-- begin field 877b2d9b-7ff7-49f6-ba59-abf5934f11a1 --><ul><li><strong>Advise the person and/or their parents/carers that:</strong><ul><li>If they have continuous pain, they should use paracetamol regularly (four times a day).</li><li>Paracetamol rarely causes adverse effects when used at the correct dosage.</li><li>There are other paracetamol-containing medicines available over-the-counter (OTC). The recommended <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/#recommended-doses\">maximum total daily dosage</a> must not be exceeded.</li></ul></li><li><strong>Provide written information on paracetamol and pain management.</strong><ul><li>The British Pain Society leaflet <a data-hyperlink-id=\"117e9632-6c21-4c3b-906d-ac0a01370395\" href=\"https://www.britishpainsociety.org/static/uploads/resources/files/patient_pub_otc.pdf\">Managing your pain effectively using “Over the Counter” (OTC) Medicines</a> discusses the short- and long-term use of OTC analgesics and their associated adverse effects.</li><li>The NHS website (<a data-hyperlink-id=\"ce42e858-f50b-454c-9ef2-ac0a013703a4\" href=\"https://www.nhs.uk/\">www.nhs.uk</a>) has information on <a data-hyperlink-id=\"4cd708c9-bc74-40fd-b685-ac12013b78fc\" href=\"https://www.nhs.uk/medicines/paracetamol-for-adults/\">Paracetamol for adults</a> and <a data-hyperlink-id=\"b77d750c-2652-44a5-a90e-ac12013b7916\" href=\"https://www.nhs.uk/medicines/paracetamol-for-children/\">Paracetamol for children (including Calpol)</a>.</li></ul></li></ul><!-- end field 877b2d9b-7ff7-49f6-ba59-abf5934f11a1 --><!-- end item f67372b5-7585-44e5-a979-c2b03984f569 -->","subChapters":[{"id":"e7ec14e2-aafa-5f1f-804c-3b1c78c6764d","slug":"basis-for-recommendation-550","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f97d1b33-3240-4112-bf5b-d6b1310660a8 --><h4>Basis for recommendation</h4><!-- end field f97d1b33-3240-4112-bf5b-d6b1310660a8 -->","summary":null,"htmlStringContent":"<!-- begin item 55053c67-e980-420c-9f9e-81e8a0f2c598 --><!-- begin field 862e13f8-542e-4a32-adf8-0e121ed0389f --><p>These recommendations are based on what CKS considers to be good clinical practice.</p><!-- end field 862e13f8-542e-4a32-adf8-0e121ed0389f --><!-- end item 55053c67-e980-420c-9f9e-81e8a0f2c598 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}